Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease

Ann E. Kearns, Sundeep Khosla, Paul J. Kostenuik

Research output: Contribution to journalArticle

511 Citations (Scopus)

Abstract

Osteoclasts and osteoblasts dictate skeletal mass, structure, and strength via their respective roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong process whereby old bone is removed by osteoclasts and replaced by bone-forming osteoblasts. The refilling of resorption cavities is incomplete in many pathological states, which leads to a net loss of bone mass with each remodeling cycle. Postmenopausal osteoporosis and other conditions are associated with an increased rate of bone remodeling, which leads to accelerated bone loss and increased risk of fracture. Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor κB ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling. The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK. Osteoclast activity is likely to depend, at least in part, on the relative balance of RANKL and OPG. Studies in numerous animal models of bone disease show that RANKL inhibition leads to marked suppression of bone resorption and increases in cortical and cancellous bone volume, density, and strength. RANKL inhibitors also prevent focal bone loss that occurs in animal models of rheumatoid arthritis and bone metastasis. Clinical trials are exploring the effects of denosumab, a fully human anti-RANKL antibody, on bone loss in patients with osteoporosis, bone metastasis, myeloma, and rheumatoid arthritis.

Original languageEnglish (US)
Pages (from-to)155-192
Number of pages38
JournalEndocrine Reviews
Volume29
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

RANK Ligand
Bone Remodeling
Cytoplasmic and Nuclear Receptors
Bone and Bones
Health
Osteoclasts
Osteoprotegerin
Bone Resorption
Osteoblasts
Rheumatoid Arthritis
Animal Models
Neoplasm Metastasis
Postmenopausal Osteoporosis
Tumor Necrosis Factor Receptors
Bone Diseases
Bone Density
Osteoporosis
Anti-Idiotypic Antibodies
Clinical Trials
Cytokines

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. / Kearns, Ann E.; Khosla, Sundeep; Kostenuik, Paul J.

In: Endocrine Reviews, Vol. 29, No. 2, 04.2008, p. 155-192.

Research output: Contribution to journalArticle

@article{e1b148f0f96e44b58a632ca8cd2b1974,
title = "Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease",
abstract = "Osteoclasts and osteoblasts dictate skeletal mass, structure, and strength via their respective roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong process whereby old bone is removed by osteoclasts and replaced by bone-forming osteoblasts. The refilling of resorption cavities is incomplete in many pathological states, which leads to a net loss of bone mass with each remodeling cycle. Postmenopausal osteoporosis and other conditions are associated with an increased rate of bone remodeling, which leads to accelerated bone loss and increased risk of fracture. Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor κB ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling. The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK. Osteoclast activity is likely to depend, at least in part, on the relative balance of RANKL and OPG. Studies in numerous animal models of bone disease show that RANKL inhibition leads to marked suppression of bone resorption and increases in cortical and cancellous bone volume, density, and strength. RANKL inhibitors also prevent focal bone loss that occurs in animal models of rheumatoid arthritis and bone metastasis. Clinical trials are exploring the effects of denosumab, a fully human anti-RANKL antibody, on bone loss in patients with osteoporosis, bone metastasis, myeloma, and rheumatoid arthritis.",
author = "Kearns, {Ann E.} and Sundeep Khosla and Kostenuik, {Paul J.}",
year = "2008",
month = "4",
doi = "10.1210/er.2007-0014",
language = "English (US)",
volume = "29",
pages = "155--192",
journal = "Endocrine Reviews",
issn = "0163-769X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease

AU - Kearns, Ann E.

AU - Khosla, Sundeep

AU - Kostenuik, Paul J.

PY - 2008/4

Y1 - 2008/4

N2 - Osteoclasts and osteoblasts dictate skeletal mass, structure, and strength via their respective roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong process whereby old bone is removed by osteoclasts and replaced by bone-forming osteoblasts. The refilling of resorption cavities is incomplete in many pathological states, which leads to a net loss of bone mass with each remodeling cycle. Postmenopausal osteoporosis and other conditions are associated with an increased rate of bone remodeling, which leads to accelerated bone loss and increased risk of fracture. Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor κB ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling. The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK. Osteoclast activity is likely to depend, at least in part, on the relative balance of RANKL and OPG. Studies in numerous animal models of bone disease show that RANKL inhibition leads to marked suppression of bone resorption and increases in cortical and cancellous bone volume, density, and strength. RANKL inhibitors also prevent focal bone loss that occurs in animal models of rheumatoid arthritis and bone metastasis. Clinical trials are exploring the effects of denosumab, a fully human anti-RANKL antibody, on bone loss in patients with osteoporosis, bone metastasis, myeloma, and rheumatoid arthritis.

AB - Osteoclasts and osteoblasts dictate skeletal mass, structure, and strength via their respective roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong process whereby old bone is removed by osteoclasts and replaced by bone-forming osteoblasts. The refilling of resorption cavities is incomplete in many pathological states, which leads to a net loss of bone mass with each remodeling cycle. Postmenopausal osteoporosis and other conditions are associated with an increased rate of bone remodeling, which leads to accelerated bone loss and increased risk of fracture. Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor κB ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling. The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK. Osteoclast activity is likely to depend, at least in part, on the relative balance of RANKL and OPG. Studies in numerous animal models of bone disease show that RANKL inhibition leads to marked suppression of bone resorption and increases in cortical and cancellous bone volume, density, and strength. RANKL inhibitors also prevent focal bone loss that occurs in animal models of rheumatoid arthritis and bone metastasis. Clinical trials are exploring the effects of denosumab, a fully human anti-RANKL antibody, on bone loss in patients with osteoporosis, bone metastasis, myeloma, and rheumatoid arthritis.

UR - http://www.scopus.com/inward/record.url?scp=42049110350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049110350&partnerID=8YFLogxK

U2 - 10.1210/er.2007-0014

DO - 10.1210/er.2007-0014

M3 - Article

C2 - 18057140

AN - SCOPUS:42049110350

VL - 29

SP - 155

EP - 192

JO - Endocrine Reviews

JF - Endocrine Reviews

SN - 0163-769X

IS - 2

ER -